Cascade screening is particularly relevant for diseases in which early diagnosis could lead to pre-emptive treatment or screening measures, as in the case of X-linked Alport syndrome caused by COL4A5 variants, where early treatment with an angiotensin-converting enzyme (ACE)-inhibitor can delay the progression of CKD [75]. This evidence concerns the gene ACE and chronic kidney disease.